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Abstract 
Due to the rapid economic growth and advancement in medical technology, many countries 
have experienced in the past decades an epidemiological transition from communicable to non-
communicable dieses (NCDs). One of the challenges in the era of NCDs is the large treatment gap, 
measured by the difference between the need for treatment and the actual provision of treatment, 
among patients with NCDs. This paper investigates the causes of treatment gap in mental 
healthcare from the perspective of economics. Specifically, we hypothesizes that people with 
mental illness face four major hurdles in seeking appropriate healthcare, namely the high 
nonmonetary cost due to stigma, the high out-of-pocket payment due to insufficient public funds 
devoted to the mental health sector, the high time prices due to low mental healthcare resource 
availability, and the low treatment benefit due to slow technology diffusion. We then use China as 
a study setting to show the country-specific evidence. Our analysis supports the above theoretical 
argument on the four access barriers, which in turn sheds light on the effective approaches to 
mitigate the treatment gap. Four policy options are then discussed, including an information 
campaign for mental health awareness, increasing public investment in primary mental healthcare 
resources, transforming the healthcare system towards an integrated people-centered system and 
capitalizing on e-health technologies.  
Key words: mental illness; treatment gap; access barrier;  
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1. Introduction 
In recent years, the rising prevalence of mental illness such as depression has led to 
widespread public and professional concern. One of the related areas on which this concern focuses 
is the large treatment gap, measured by the difference between the need for and the actual provision 
of treatment among patients with mental illness. It was estimated that at least 10% of the global 
population is affected by one or more mental disorders; however, according to the estimation by 
the World Health Organization, more than three quarters of those with severe mental disorders in 
the low- and middle-income countries receive no medical treatment. Although the situations in 
high-income countries are better, there are still a higher proportion, ranging from 35% to 50%, of 
patients with mental illness go untreated (WHO, 2013).  
The questions that this paper tries to answer are (1) why so many patients with mental illness 
go untreated, and (2) how to bridge the treatment gap for them. We first provide economic 
perspectives to explain the causes of treatment gap in mental healthcare. Specifically, we propose 
a testable hypothesis that patients with mental illness face four major hurdles in access to the 
appropriate care, including stigma, high out-of-pocket payment, low availability of mental health 
resources and the slow diffusion of new medical knowledge and technology. We then use China 
as a study setting to show the evidence in support of this four-hurdle hypothesis. Furthermore, 
based on both theoretical reasoning and empirical evidence, we propose four policy options to 
bridge the treatment gap in mental healthcare. Although our empirical evidence and policy 
discussion lie in the context of China’s health system, our findings also have important 
implications for other low- and middle-income countries with similar development experience and 
challenges in the healthcare sector.  
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Our study contributes to the growing body of research on mental health policy designs in 
developing countries. In the academic community, many studies have attempted to provide 
quantitative evidence on the magnitude of the treatment gap in mental healthcare (Kohn et al., 
2004; Patel et al., 2016). However, little research has investigated the causes of treatment gap in a 
systematic way. In the policy area, several international agencies have identified the major 
roadblocks of receiving treatment in mental health, including stigma, inadequate funding, and poor 
design of health system (The World Bank Group and WHO, 2016). However, there is virtually no 
research to discuss further on the rooted factors that shapes such roadblocks, especially in low- 
and middle-income countries. Our research aims to provide a synthesis for the various academic 
endeavors and policy discussions on how to help patients with mental illness get out of the shadow 
and receive the appropriate diagnosis and treatment. It provides a relatively general framework by 
integrating institutional analysis with economic analysis of healthcare-seeking behavior to achieve 
a better understanding on the causes of the treatment gap. Based on this analytical framework, we 
then propose several policy options on bridging the treatment gap in the mental health sector.  
 
2. Conceptual Framework  
The economic theory of healthcare-seeking behavior states that individuals will seek for 
mental healthcare as long as the expected benefit of doing so exceeds its expected cost. Based on 
this framework, the low treatment rate of mental illness can be explained by two potential reasons: 
the cost is too high and / or the benefit is too low. A closer look of mental healthcare delivery 
indicates that the costs of seeking treatment include both monetary and nonmonetary costs. The 
nonmonetary cost is mostly due to the stigma associated with mental illness. The full monetary 
costs that the patients pay for receiving treatment can be further divided into two parts: (1) the 
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financial prices of mental healthcare as reflected by the patient out-of-pocket payment; and (2) the 
time prices of seeking mental healthcare as reflected by the opportunity cost of patient’s time 
allocated to travelling, waiting and receiving treatment (Sloan and Hsieh, 2017).  
Compared to physical illness, a most distinctive feature associated with mental illness is 
stigma. Specifically, negative consequences of stigma decrease patients’ opportunity of seeking 
employment and housing, increase patients’ family stress, and lower their quality of life. The fear 
of status loss and discrimination in turn becomes the internal cost and a major barrier for patients 
with mental illness to overcome when they seek medical treatment. This implies that the non-
monetary cost imposed by social stigma is the first hurdle in the access to mental healthcare.   
The second hurdle in seeking mental healthcare is the money price in the form of patient out-
of-pocket payments for mental healthcare utilization. As shown in the WHO report, many countries 
(especially low- and middle-income countries) suffer from the under-funding problem in the sense 
that the public sector allocates an extremely low share of health budgets into the mental health 
sector (World Bank Group and WHO, 2016). According to a recent survey conducted by WHO, 
governments spend on average 3% of their health budgets on mental health (a figure much lower 
than the non-mental health sector such as hypertension and diabetes), with a distribution from 0.5% 
in the low-income countries to 5.1% in the high-income countries (WHO 2014; World Bank Group 
and WHO, 2016). A natural consequence of the under-funding problem is that patients with mental 
illness typically need to pay a higher out-of-pocket amount to finance their treatment compared to 
their counterparts with physical illness. 
Thirdly, many countries do not have sufficient healthcare resources (including mental health 
personnel and facilities) to deliver the appropriate care to patients with mental illness.  The low 
availability of mental health resources is mainly reflected in two dimensions: (1) inadequate 
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capacity building in the training of mental health professionals, which leads to the overall 
insufficient supply in the mental healthcare market; (2) the limited resources for mental healthcare, 
including both professionals and facilities, are usually concentrated in the densely-populated urban 
areas within a country, indicating an uneven geographic distribution of mental healthcare resources. 
One of the significant consequences of insufficient and maldistribution of healthcare resources is 
the increase in time cost for seeking mental healthcare, which in turn becomes the third hurdle for 
people suffering from mental health conditions, such as depression.  
Finally, the fourth hurdle in accessing mental healthcare is the low expected benefits of 
treatment arising from the technology gaps between the frontier of new knowledge in treatment 
procedure and the local practice styles available to patients. Although there has been a rapid 
development in medical knowledge and technology for mental healthcare in recent years, whether 
the frontier of these new technology and knowledge can be transmitted to become a prevailing 
local practice standard depends on the speed of knowledge diffusion and technology adoption. 
Many studies have shown the evidence that the incentives for innovation in general and the 
technology diffusions in particular are positively correlated with the market size (Acemoglu and 
Lin, 2004; Berndt and Cockburn, 2014). As mentioned, many countries face common challenge of 
inadequate funding in their mental health sectors, indicating that mental healthcare has a relatively 
smaller market size as compared to that of the general healthcare. As a result, mental health sector 
is in disadvantage in facilitating technology diffusion such as the launch of new prescription drugs. 
This in turn enlarges the gap between the frontier of treatment know-how and the local practice 
standards in those countries. The existence of such a knowledge gap and outdated clinical practice 
may reduce the potential benefits of mental health treatment, which in turn further decreases the 
incentive for the patients to seek medical assistance when in need.   
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In summary, the above analyses indicate that people with mental illness face higher marginal 
costs of accessing mental healthcare than other patients, including the psychological cost imposed 
by social stigma, the out-of-pocket cost arising from the low public funding, the time cost due to 
the poor availability of mental healthcare resources. In addition, the perceived benefits of medical 
treatment may be lower due to the slow diffusion of new medical knowledge and technology. We 
hypothesize that these four hurdles largely explain why many people with mental illnesses tend to 
significantly delay the opportunity to seek treatment or go completely undiagnosed, a stylized fact 
in epidemiological studies in many countries (Bor, 2015). In the next section, we use China as an 
example to show the evidence for this four-hurdle hypothesis.  
 
[Insert Figure 1 Here] 
 
3. Empirical Evidence from China 
3.1 Stigma 
Social stigma normally appears in the form of shame among patients with mental illness, and 
this psychological burden is shown by many studies to be heavier in the Chinese culture. According 
to Triandis (1989), in individualistic cultures (such as UK and US), individual behavior is often 
determined by personal goals; while in collectivist cultures (such as Greece and China), in-group 
goals are more important. Thus, mental illness patients in the collectivist cultures are easily 
attached with a negative image due to their mental and behavioral inconsistency with social norms. 
Based on a survey of 305 individuals from four UK-based cultural groups (white-English, 
American, Greek / Greek Cypriot, and Chinese), Papadopoulos et al. (2013) find that the Chinese 
group holds the most stigmatizing views among the four racial groups, indicating that the culture-
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specific attitude towards mental illness may not be quickly moderated by international migration 
or by interacting with other cultural groups. In light of the “community attitudes towards mental 
illness scale” and the “vertical-horizontal individualism-collectivism scale”, the authors also 
conclude that people with mental illness are more likely to be publically stigmatized within the 
collectivist cultures than the individualistic cultures.  
Similarly, Bharadwaj et al. (2015) provide evidence to support the existence of stigma 
associated with mental illness: by comparing self-reports to administrative data records, they find 
that more than one-third of the survey respondents under-report mental health conditions; by 
contrast, the respondents are less likely to under-report their physical illnesses such as diabetes or 
hypertension.  This study also finds that individuals from Asia are more likely to under-report than 
their counterparts from Northern Europe and the United States, indicating that stigma may play a 
more important role in the Asian cultures, many of which share similar characteristics with the 
Confucians culture in China, and may become a major obstacle for these patients.   
WHO has pointed out the long-term negative effects of stigma, highlighting that stigma, as a 
major source of discrimination and exclusion, can damage patients’ self-esteem, disrupt their 
family relationships, and consequently limit their ability and willingness to socialize, obtain 
housing and seek employment. Table 1 presents the comparative statistics between different 
mental health groups in China based on data from China Family Panel Studies (2012), a nationally 
representative household survey. It shows a significant correlation between the respondents’ 
mental health status and their ideology and social economic status. People with mental depression 
or depressive symptoms (classified based on the CES-D scores) are shown to have significantly 
lower life satisfaction on family and themselves, less self-confidence and lower trust towards 
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family members and other social groups. 58.4% of the mentally healthy people, compared to only 
37.5% of people with depression, tend to believe that most people are trustworthy.  
In fact, stigma has been reported to hamper the prevention and treatment of mental health 
disorders and the promotion of mental well-being (WHO 2017), which in turn results in poorer 
physical healthcare, suicidality, and higher mortality rates (Thornicroft et al. 2007). Stigma has 
been identified by mental health service users as a considerable cause of suicide attempts, and as 
potentially more damaging than the mental illness itself (Eagles et al. 2003). For example, based 
on interviews with close associates of people who committed suicide and of people who died from 
other injuries in China, Phillips et al. (2002) find that a high depression symptom score remains a 
significant predictor for suicidality after adjusting for sex, age, residential location and other 
factors. Corrigan et al. (2005) also find that the negative impacts of stigma are likely to extend 
from the daily life of patients to that of their family members, friends and even mental health 
provider groups, implying a negative spill-over effect of social stigma.  
The long-term consequences of stigma among the mentally ill may also extend from health 
outcomes to their labor market outcomes. For example, using the National Co-morbidity Survey-
Replicate (NCS-R) data, Chatterji et al. (2011) find that psychiatric disorders are associated with 
reductions of 9% and 14% of the labor force participation rate and the employment rate for male. 
Peng et al. (2013) estimate that depression leads to an annual work loss of about 1.4 days 
(accounting for 33% of total health-related workday loss). The CFPS 2012 dataset provides 
additional evidence of stigma in China’s labor market: for example, the years of education and the 
levels of personal income are shown to be significantly lower for people with mental depression 
or depressive symptoms compared to the mentally healthy respondents. On average, the mentally 
healthy people acquire 7.6 years of formal schooling, which is almost twice as much as the average 
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education years of people with depression; the annual income of people who are mentally healthy 
is 50% higher than those with depressive symptoms and triple that of people with depression (see 
Table 1). 
 
 [Insert Table 1 Approximately Here] 
 
3.2 Out-of-pocket costs of mental healthcare 
Although China has made significant progress in achieving the goal of universal coverage, the 
current system has substantial variation among more than 3,000 health insurance plans in terms of 
their eligibility criteria, design of insurance benefits and co-payment schemes (Meng et al., 2015). 
More specifically, different health insurance plans, such as the New Rural Cooperative Medical 
Scheme (NCMS, a government subsidized plan covering all rural families), the Urban Employee 
Basic Medical Insurance (UEBMI, a social insurance program financed by employers and 
employees covering urban workers in the formal sectors) and the Urban Resident Basic Medical 
Insurance (URBMI, an urban health insurance scheme covering informal sector workers and 
people without employment), differ in their enrollment criteria and co-insurance rates. Within each 
plan, coinsurance and copayment rates also differ by regions and types of treatment. Generally 
speaking, the copayment rates for outpatient visits are higher than those for inpatient admissions 
in China, especially for rural health insurance programs.  
Before 2012, the insurance coverage and reimbursement for mental healthcare are usually 
limited and dependent on the provincial government’s financial capacity. In 2012, the Chinese 
central government announced the decision to expand the coverage of the country's healthcare 
insurance system to include the treatment of critical illnesses including major mental diseases. 
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Meanwhile, the Mental Health Law of China was launched in 2013, which formalizes the legal 
protection and treatment of people with mental disorders. After these milestone steps in 
strengthening the mental healthcare system, both the outpatient and inpatient medical expenses of 
mental health patients are gradually covered in China’s national health insurance system. For 
example, Beijing included six types of major mental diseases (e.g. Schizophrenia, Paranoia, 
Bipolar disorder, etc.) into its insurance plan in 2014 and increased the reimbursement rates for 
the inpatient and outpatient healthcare for these conditions from 60% to 70% with no maximum 
payment limits; in addition, the essential drugs for the treatment of these major mental diseases 
are also made free to outpatients, which has benefited more than 12,000 mental health patients by 
2016. Shanghai included four mental disease into its Critical Disease Insurance Plan in 2015, 
which provides a 50% reimbursement rate (increased to 55% in 2017) in supplement to the basic 
health insurance coverage.  Several cities in China’s eastern coastal provinces, including Jinan, 
Zhanjiang, Foshan and Dongguan also witnessed an inclusion of mental diseases into their health 
insurance plan in 2015. The city of Shenzhen covered six mental diseases in 2016 with maximum 
reimbursement rates of up to 90%. In the rural sector, NCMS started to launch pilot programs to 
cover mental diseases and other critical illnesses in 2013. Meanwhile, the average government 
financial support for the NCMS program increased from 320 RMB (about $53) per person in 2013 
to 450 RMB (about $75) per person in 2017. However, there is substantial variation across regions 
in the time and rates of reimbursement for the mental illnesses within NCMS.  
Despite the above-mentioned progress in extending health insurance coverage for mental 
illnesses, China still suffers from serious maldistribution in the coverage and reimbursement rate 
for mental diseases. High-income areas such as the eastern coastal regions and major urban cities 
usually enjoy better coverage as well as higher reimbursement rates. For example, based on the 
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1989-2011 data of the China Health and Nutrition Survey (CHNS), we estimate the effective 
reimbursement rates (total medical expenditure less the patient out-of-pocket payment) for mental 
healthcare and non-mental healthcare in China’s nine provinces (see Figure 1). As indicated, 
patients with mental health problems in the eastern provinces enjoy a significantly higher effective 
reimbursement rate compared to their counterparts in the Northeast, Central and the West. In 
addition, compared with the reimbursement rates of physical conditions such as heart disease, 
tumor and respiratory diseases, the mental illness patients that are surveyed in the 1989-2011 
CHNS receive a lower average reimbursement rate (10.46% vs. 16.61%). Therefore, there is 
substantial variation not only in insurance coverage across regions, but also in health benefit 
packages between the general healthcare and mental healthcare. Given such maldistribution of 
financial support from health insurance plans, patients with mental health problems in lower-
income areas would face higher out-of-pocket burden, which in turn deters the proper use of mental 
healthcare treatment.  
 
[Insert Figure 1 Approximately Here] 
 
3.3 Mental healthcare resources 
Much of the access barrier for mental healthcare in China is due to the limited supply and 
unequal distribution of professional mental healthcare resources. For example, China only had 
1.46 psychiatrists per 100,000 population in 2010, which was substantially below the global 
average mental health workforce (4.15 psychiatrists per 100,000 population) (Liu et al., 2011; Qian, 
2012). The lack of qualified mental health professionals may be partially due to the government 
control of medical education and accreditation, and it may also be attributed to the severe under-
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diagnosis of mental illnesses that results in the mismatch of supply and the potential demand of 
mental healthcare. According to Fan et al. (2013), over 100 million Chinese experience different 
kinds of mental disorders during a year, and these mental diseases account for over 20% of the 
total burden of diseases in China. Given the high prevalence rate of depression (4.08%) in China 
estimated by Qin et al. (2016), the medical resource of mental health care is relatively scarce 
compared to the general health care. In addition to the overall undersupply of manpower, 
geographic mal-distribution of available mental health resources in China and the concentration of 
qualified personnel in the urban-based psychiatric hospitals indicate that mental health services 
are quite limited in rural areas (Philips et al., 2009).  
To illustrate the above points, Table 2 compares the mental healthcare resources and general 
healthcare resources between 2010 and 2015 in China. A cross-sectional comparison indicates that 
in 2015, the number of licensed doctors in the mental healthcare sector contributes to only 0.9% 
of the total supply of licensed doctors, and the number of hospital beds in the mental health sector 
accounts for only 1.1% of total hospital bed capacity in China. A time series comparison indicates 
that while the physician density of general healthcare has increased from 18.0 per 10,000 
population in 2010 to 22.2 in 2015, the density of licensed mental healthcare physicians decreased 
from 0.234 per 10,000 population in 2010 to 0.199 in 2015. In contrast with the stable growth in 
the density of general healthcare doctors, the growth rate of licensed doctors in the mental health 
sector has fluctuated between -21.79% to 6.32% in recent years. The annual growth rate of hospital 
beds in mental health is also significantly lower than that in the general health care until 2014.  
 
[Insert Table 2 Approximately Here] 
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One of the plausible reasons for the undersupply of mental healthcare manpower is that the 
profession offers less attractive wage payment and working environment compared to other 
specialties of medical care. Table 3 presents the service revenue, service costs and the implied 
gross profit rates of different specialty hospitals in China based on the public data in the national 
health statistical yearbook of 2016. Compared to the profit-generating specialties such as plastic 
surgery (83.3%), ophthalmic (52%) and rehabilitation (42.4%), the psychiatric hospitals (16.8%) 
rank comparatively low in the profit rates in year 2015, despite their relatively high annual revenue 
of 29.6 million Yuan per hospital. Given that most hospitals in China rely on their own profits for 
daily operation and physician employment, the above comparison indicates that the prospective 
income is lower for mental health doctors compared to doctors in other specialties, which suggests 
that the mental health profession may fail to attract sufficient personnel in the long term. 
 
[Insert Table 3 Approximately Here] 
 
In addition to low wage payments, the intense relationship between patients and doctors in 
China also contributes to the shortage of manpower in the mental healthcare sector. Due to their 
distrust on the profit-seeking behaviors of medical institutions, many patients and their family 
members in China prefer to use “medical disturbance” (Yi Nao) or “medical violence” (Yi Bao) 
against the individual doctors when they are not satisfied with their treatment outcome (Tucker et 
al., 2015). For examples, they may hire a third-party gangster to harass or even attack the doctor 
for the financial compensation of an actual or perceived medical malpractice.  This behavior has 
resulted in an increasingly uncomfortable and even dangerous working environment for physicians 
in China. According to a survey conducted by the Chinese Hospital Association in 2012 and 
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2013, violence against medical staff has increased from 20.6 assaults per hospital in 2008 to 27.3 
in 2012, based on data from 316 hospitals in more than 30 provinces (Jia et al., 2014). Compared 
with patients in the general healthcare sector, patients with mental health problems may be even 
more prone to violent behaviors for ineffective medical treatment, and this can make the specialty 
of mental healthcare a less attractive option for doctors and medical students making career choices 
due to their additional safety concerns with the working environment. 
In addition to the insufficiency of overall mental healthcare capacity, the geographic mal-
distribution of available mental health resources in China is another concern. Figure 2 maps the 
provincial density of hospital beds in psychiatric departments in 2015. The figure indicates that 
there is dramatic disparity in mental healthcare resources across the country: the economically 
developed eastern provinces such as Shanghai and Zhejiang enjoys higher densities of psychiatric 
hospital beds, while the economically less developed inland regions in Central and Western China 
are in dire need of mental health resources. The most underdeveloped provinces such as Qinghai, 
Gansu, Ningxia and Guizhou have extremely low densities of hospital beds for professional mental 
health treatment. Given that the prevalence rates of depression and depressive symptoms are also 
higher in central and western provinces (Qin et al., 2016), the above findings indicate that the 
inland regions suffer from the most severe problem of unmet medical needs in mental healthcare.  
 
[Insert Figure 3 Approximately Here] 
 
3.4 Diffusion of new medical knowledge and technology in mental healthcare 
Under the current practices in China’s healthcare sector, two institutional features may 
enlarge the technology gaps in the field of mental healthcare. First, due to the lack of government 
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subsidy for low service fees charged by public hospitals, healthcare providers in China rely heavily 
on profits obtained from prescription drugs as their major sources of revenue, indicating that 
physicians may choose to prescribe drugs based not on efficacy, safety or cost, but solely on the 
extent of the profit margins that they or their institutions obtain (Yang 2016). Second, due to the 
Essential Drug Policy and the regulated insurance reimbursement schedule, there may be a long 
delay in the launch of new mental healthcare drugs or treatment procedures in China; as a result, 
physicians may not be able to prescribe what proves to be the most effective treatment regimes, 
and this translates to another policy-induced barrier for the mental illness patients in China.  
Burns and Liu (2017) illustrate the evidence on the complex market access hurdles for 
pharmaceutical products in China. For companies who are registering patented or differentiated 
generic drugs, the whole process usually lasts for about 4-6 years, involving the following steps: 
registration and approval of new drugs, pricing and bidding, reimbursement listing at the local and 
national level, and at last hospital listing. More specifically, provincial bidding is held every two 
years or so; national reimbursement listing takes place every four to five years; another two years’ 
time is spent on the hospital listing process. As such, for a domestic or multinational 
pharmaceutical company to launch a new drug in China, it has to wait seven years on average for 
drug approval, launching and listing in the target hospitals. Companies are not allowed to sell new 
drugs on the market until the above process is fully completed. This results in a wide gap in the 
launch of new and innovative drugs between China and high-income countries such as U.S., Japan 
and U.K. This is illustrated in Figure 4, which shows that the initial market share of new drugs in 
China (2.5%) is considerably lower than that in U.S. (56.3%), Japan (12.6%), U.K. (7.7%), 
Germany (6.5) and Korea (3.1%) in year 2015. Given that the knowledge and technology frontier 
in the mental health treatment witnesses fast expansion in recent years, the above statistics suggests 
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that the mental illness patients in China are less likely to benefit from the most innovative drugs 
and treatment options compared to their counterparts in the above mentioned countries.  
 
[Insert Figure 4 Approximately Here] 
 
There is ample evidence to illustrate the slow adoption of mental health drugs in China 
compared with the high income countries, taking the United States as an example. First, as Table 
4 illustrates, among 12 new molecular entities for Central Nervous System (CNS) diseases 
available in the global market, only one was launched in China. By contrast, eight drugs are 
adopted in the United States. This indicates the difference in the adoption rate between U.S. and 
China is 0.583 (8/12 minus 1/12). Furthermore, the difference in adoption rates between CNS 
drugs and drugs for other NCDs in China is 0.094, which is higher than that of the United States 
(0.01). Therefore, not only China has a slow adoption of new drugs, but its adoption of drugs for 
mental illness are even slower than that for other non-communicable diseases. Second, Table 5 
takes 14 atypical antipsychotic medicine as examples, and shows the year in which these mental 
health drugs were approved by the U.S. Food and Drug Administration (USFDA) and whether 
they were approved to be marketed in China by year 2016 by the China Food and Drug 
Administration (CFDA). As indicated, drugs approved by USFDA before 2009 have all been 
marketed in China, but only 1 out of the 7 drugs approved by USFDA after 2009 has been marketed 
in China by 2016, which suggests a long delay in the launch of new pharmaceutical products in 
China’s mental health sector.  
 
[Insert Table 4 Approximately Here] 
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 [Insert Table 5 Approximately Here] 
 
Another piece of evidence for the knowledge gap comes from the comparison of clinical 
guidelines for the first-line drug prescription on mental health conditions between China and the 
developed countries (see Table 6). Clinical guidelines for the treatment of mental depression 
started to be published in China from 2006, the first edition of which is only 5 pages long (Chinese 
Medical Association, 2006). The guideline was still officially recommending the use of TCAs (a 
category of first-generation antidepressant with considerable adverse drug reaction), while at the 
same time second-generation antidepressants such as SSRIs and SNRIs had been widely marketed 
in U.S. and other developed countries for more than a decade due to their effective treatment and 
less side effects (Gelenberg et al., 2010). This represents a clinical knowledge gap between China 
and developed countries as well as a technology gap in the pharmaceutical industry. The second 
edition of official guidelines for the treatment of depressive disorders was published in 2015, with 
much more detailed and up-to-date content, recommending SSRIs, SNRIs and NaSSAs as first-
line treatment options for mental depression (Chinese Medical Association, 2015). However, there 
still existed a large know-do gap between the official recommendation and the field practices in 
China, and first-generation therapies such as TCAs and TeCAs were still commonly prescribed by 
mental health doctors in various regions of China.  
 
[Insert Table 6 Approximately Here] 
 
Other than the regulation-induced barrier to the diffusion of medical knowledge and 
technology, the persistent under-funding problem of the mental health sector also enlarges the gap 
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between the technology frontier and the local treatment practice in China. Figures 4 and 5 present 
the market shares (measured as the number of outpatient visits or inpatient discharges for a specific 
service type as a percentage of total number of outpatient visits or inpatient discharges) of various 
types of diseases among China’s medical institutions in 2015. As indicated, both outpatient and 
inpatient shares of psychiatry (mental health department) account for merely 1% among all types 
of healthcare services, suggesting that the mental healthcare sector accounts for a very small size 
in the overall healthcare sector in terms of patient volumes and service revenues. Given that the 
public and private funds tend to flow into major sectors with large market sizes (such as internal 
medicine and traditional Chinese medicine), the under-funding problem is expected to plague 
China’s mental health sector in the foreseeable future and in turn reduce the speed of technology 
adoption in local practices. The vicious cycle of under-funding and under-treatment is thus 
exacerbated by the treatment gap, leading to further reduction in the potential effectiveness of 
mental healthcare services in China. 
 
[Insert Figure 4 Approximately Here] 
 [Insert Figure 5 Approximately Here] 
 
4. Policy Options for Bridging the Treatment Gap 
Given the evidence that high costs and low benefits are two main causes of under-treatment 
in mental healthcare, we offer two approaches to bridge the treatment gap: the “push incentives” 
and the “pull incentives”, which are designed to reduce the costs of treatment and to increase the 
benefits of treatment, respectively. For push incentives, we suggest three policy options to reduce 
the nonmonetary cost, out-of-pocket cost and time cost in the mental healthcare seeking process. 
For pull incentives, we suggest using the information and communication technology (ICT) to 
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speed up the technology diffusion and hence to increase the quality (benefit) of the treatment. We 
discuss all these policy options in the following subsections.  
4.1 Out of the shadow: Information campaign for the awareness of mental illnesses 
Given the high prevalence rates of mental disorders in China, it is important to educate the 
public through information campaigns to increase the awareness of mental illnesses. In addition, 
an anti-stigma campaign would be beneficial to reduce the nonmonetary cost of seeking mental 
healthcare. In the Chinese traditional culture, some forms of the stigma associated with mental 
disorders arise from the names of mental illnesses per se. Thus, an effective approach to mitigate 
the stigma is to rename the diseases to eliminate the negative bias inherent to the name tag and to 
give the medical condition a neutral image. Table 7 lists the traditional names of mental illnesses 
in the Chinese language (Mandarin) that contain a strong stigma as well as the suggested new 
names that may substantially reduce the stigma associated with the medical condition.  
 
[Insert Table 7 Approximately Here] 
 
International experiences also suggest that mass media campaigns made by trusted sources 
(such as professional medical associations) can also contribute to reduce the social stigma and 
encourage patients with mental diseases to seek proper healthcare. For example, an advertisement 
campaign in Germany made by Phychenet features a patient suffering from mental illness, which 
demonstrates and explains the symptoms and prevalence of mental diseases with warm-hearted 
encouragement for people with such symptoms to seek help. This campaign has successfully raised 
the public awareness of mental diseases and let patients know that many other people are suffering 
from the same health conditions, which in turn helped to reduce the self-perceived stigma among 
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these patients. Similar mass media campaigns have been experimented in various parts of China, 
with government-financed advertisement displayed on TV, on large advertisement boards in 
densely populated areas (such as subway stations) and within hospitals.  
4.2 Increasing the public investment in mental healthcare  
Currently, the public funds allocated to mental health sector only accounts for less than 1% 
of total health expenditure in China. Thus, China still has ample room for increasing the public 
investment in mental health resources. Two main channels are feasible for the public funds to enter 
the mental health sector: one is through the direct subsidy to the mental health institutions as 
financed by the general tax revenues, and the other is through an earmarked tax by specifically 
including or enhancing the mental health benefit package in the existing health insurance programs.  
The advantage for the direct public subsidy to mental health facilities is to mitigate the price 
distortion toward the profit-seeking treatment. For example, the relative price of essential 
psychotropic medications for the treatment in mental healthcare is low because many of them are 
now off patent. But this does not mean that physicians have incentives to prescribe these cost-
effective medicine. Under the current profit-centered health system, physicians do not have 
incentives to prescribe the most cost-effective prescription drugs to their patients. Rather, they tend 
to prescribe revenue-generating drugs. The increase in public investment through the direct 
government subsidy to mental health facilities is beneficial to reducing such behavioral distortion 
among physicians and hence increasing the efficiency of mental healthcare by lowering the costs 
and achieving a better outcome for the treatment. The advantage of the second financing channel 
is to reduce the out-of-pocket payment for the patients with mental illnesses, which in turn provides 
push incentives for these patients to seek appropriate treatment.   
A recent study suggests that increasing public funds provides a strong return on investment, 
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ranging from 2.3 to 5.7 per dollar (Chisholm et al., 2016). Although the argument is clear, the 
government needs to have a strong motivation to take action. One of such motivations is to treat 
mental health as a public good (an important component of public health with social benefits) 
instead of private good (a personal healthcare matter) (Qian 2012), which in turn provides a 
justification for the government to increase the public investment in the mental health sector.  
4.3 Integrated people-centered health system 
Many studies have shown that the current hospital-centered health system in China is not an 
efficient approach to bridge the treatment gap in mental healthcare. Rather, an effective 
intervention and treatment model is to deliver the mental healthcare at the primary and community 
level. There are at least three arguments to support the urgent need to restructure the current 
delivery system for mental health services. First, hospital-centered health system is more likely to 
be subject to the constraint of maldistribution of healthcare resources across regions. By contrast, 
primary care facilities are relatively easy to access at the community level. As a result, a natural 
consequence of a shift from the hospital-centered to the primary-care-oriented system is to reduce 
the time cost of diagnosis and treatment, which in turn would provide strong push incentives to 
bridge the treatment gap. Second, a people-centered system, which integrate primary, maternal, 
and the care for other NCDs together, is in a better position to address the co-morbidities of mental 
illnesses and the common co-existence of risk factors, such as hypertension and obesity. Third, 
mental health is also strongly correlated to economic poverty and poor lifestyle choices (such as 
malnutrition and physical inactivity), an integrated system is beneficial in the sense that it provides 
an effective treatment by integrating mental healthcare with anti-poverty policies and other disease 
management programs. In sum, an integrated people-centered delivery model can be a viable 
choice to break the cycle of economic poverty, under-treatment of mental illnesses, and the co-
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morbidity with other NCDs.  
4.4 e-health system 
One major barrier for developing the integrated people-centered primary care system in China 
is that the primary care is often perceived as low-quality care. An effective policy option for 
breaking this perception is to develop an ICT-based platform, or the e-health system, to inform the 
public about mental healthcare options and to facilitate the remote and data-based healthcare 
practices. This in turn have the potential to increase the benefits of receiving treatment in the form 
of quality improvement and cost reduction in mental healthcare. There are several benefits 
associated with the development of ICT. First, using digital healthcare is an effective approach to 
reduce the regional inequality in accessing mental healthcare resources, especially the quality and 
technological gap between the urban and rural areas as well as between large hospitals and primary 
care institutions. Second, ICT offers alternative models of delivering mental healthcare by 
mitigating many access barriers in the current system, including the transportation barriers, the 
perceived stigma associated with visiting mental health clinics, clinician shortages, and the slow 
diffusion of medical technology from urban to rural areas. Third, ICT has a potential to bridge the 
treatment gap in mental healthcare by providing remote screening, diagnosis, monitoring, 
treatment and even remote training for non-specialist healthcare workers.  
 
5 Conclusions 
It has been widely recognized that there are substantial unmet mental healthcare needs, or the 
large gap between the need for and the provision of treatment. This paper contributes to increasing 
our understanding on the causes of treatment gap in mental healthcare from the perspectives of 
economics. We hypothesize that mental healthcare faces more access barriers than the general 
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healthcare. Based on the institutional features in China’s health system, we find evidence to 
support our hypothesis on the four major hurdles in accessing mental healthcare, namely, the 
nonmonetary costs associated with stigma, the monetary costs due to the limited insurance 
coverage and reimbursement, the time costs that results from the geographic maldistribution of 
healthcare resources, and the poor healthcare quality due to the slow diffusion of new knowledge 
and technology in the mental health sector.  
An important implication of our study is that removing access barriers to mental healthcare is 
a multi-tasking work, suggesting that a single policy tool is not sufficient to mitigate the treatment 
gap in mental healthcare. Previous policy efforts to remove access barriers have been focused on 
reducing the monetary cost of mental healthcare through expanding health insurance coverage and 
on reducing the time costs through a redistribution of health care resources. Our analysis indicates 
that more policy tools and further actions are needed. Specifically, we propose an information 
campaign for mental health awareness and we suggest properly rename the mental health 
conditions in the Chinese language, both of which aim to reduce the social stigma in public 
perception and to reduce the nonmonetary costs of seeking mental healthcare. In addition, we also 
call for more policy efforts to accelerate the process of new drug launch and the adoption of new 
medical technology in the treatment of mental illnesses, which helps to increase the quality and to 
close the treatment gap of mental healthcare.    
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Table 1 Differences in Psychological and Socio-economic Characteristics among Three 
Mental Health Groups in China, 2012 
 
Notes: (1) Data Source: China Family Panel Studies (2012). (2) Mental health status (Mhs) is divided into 
three groups: mentally healthy group, group with depressive symptoms and group suffering from severe 
depression, which are categorized using the CES-D score (mentally healthy = CES-D at 15 or lower; 
depressive symptoms = CES-D between 16 and 27; depression = CES-D at 28 or higher). (3) The statistics 
reported are sample means within each mental health status group, with standard deviation in parenthesis. 
ANOVA test with the null hypothesis that the mean values of different mentally health status groups are the 
same is provided. *** denotes statistical significance at 1% level. 
  
 Mentally 
healthy 
Depressive 
symptoms 
Severe 
depression 
Life Satisfaction and Confidence    
satisfaction of one's family (from 1 to 5) 3.645 3.197 2.754*** 
 (0.976) (1.053) (1.218) 
social status of one's family in local area (from 1 to 5) 0.902 0.996 1.177*** 
 (2.928) (2.708) (2.466) 
satisfaction of one's life (from 1 to 5) 3.485 3.037 2.618*** 
 (0.99) (1.049) (1.202) 
social status of oneself (from 1 to 5) 2.745 2.554 2.391*** 
 (0.982) (1.059) (1.213) 
degree of confidence to one's future (from 1 to 5) 3.874 3.367 2.736*** 
 (1.006) (1.153) (1.361) 
Tendency to Trust Other People    
most people are trustworthy (1=yes; 0=no) 0.584 0.482 0.375*** 
 (0.493) (0.5) (0.484) 
do you trust your parents (from 0 to 10) 9.278 8.881 8.448*** 
 (1.485) (1.828) (2.288) 
do you trust your neighbor (from 0 to 10) 6.567 6.015 5.65*** 
 (2.138) (2.241) (2.638) 
do you trust the doctors (from 0 to 10) 2.189 2.29 2.642*** 
 (6.686) (6.362) (6.01) 
do you trust the cadres (from 0 to 10) 2.424 2.481 2.857*** 
 (4.924) (4.68) (4.529) 
do you trust strangers (from 0 to 10) 2.264 2.045 1.943*** 
 (2.14) (2.066) (2.257) 
do you trust the American 2.526 2.426 2.678*** 
 (2.564) (2.439) (2.465) 
    
Labor Market Outcomes     
years of education by 2012 7.625 5.958 3.992*** 
 (4.764) (4.953) (4.627) 
personal annual income (in 1000 Yuan) 13.42 8.694 4.703*** 
 (36.95) (25.23) (10.21) 
    
Observations 16503 6104 1114 
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Table 2. Capacity and Annual Growth Rate in Healthcare Resources in China: Mental 
Health Sector vs. General Healthcare (2010-2015) 
   Health care sector 2010 2011 2012 2013 2014 2015 
Number of licensed doctors 
(per 10,000 population) 
General health care 18.0 18.3 19.4 20.4 21.2 22.2 
Mental health care 0.234 0.183 0.174 0.185 0.190 0.199 
Growth rate of licensed 
doctors (%) 
General health care  1.67 6.01 5.15 3.92 4.72 
Mental health care   -21.79 -4.92 6.32 2.70 4.74 
Number of hospital beds 
(per 10,000 population) 
General health care 35.76 38.36 42.40 45.50 48.45 51.12 
Mental health care  0.45 0.48 0.49 0.54 0.58 
Growth rate of hospital beds 
(%) 
General  health care  7.27 10.53 7.31 6.48 5.51 
Mental health care    6.67 2.08 10.20 7.41 
 
Notes: (1) Data Source: Health Statistical Yearbook of China (2011-2016), National Bureau of Statistics of the 
People’s Republic of China. (2) The statistics reported are density of licensed doctors, density of hospital beds 
and their annual growth rate from 2010 to 2015 for general health care sector and mental health care sector 
respectively. General health care include mental health care and other specialty such as internal medicine, 
paediatrics and gynaecology.  
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Table 3. Estimated Profit Rates of Specialty Hospitals in China, 2015 
  
Number of 
hospitals 
Average medical 
service revenue 
(1,000 yuan) 
Average medical 
service costs 
(1,000 yuan) 
Profit rate (%) 
    Cosmetic hospital 228 19,649 8,228 138.8 
    Plastic surgery hospital 57 19,850 10,828 83.3 
    Ophthalmic/eye hospital 455 28,825 18,964 52.0 
    Rehabilitation hospital 453 12,354 8,675 42.4 
    Stomatological hospital 501 24,173 17,146 41.0 
    Others  1290 17,135 12,658 35.4 
    Hospital of dermatology 163 13,274 9,923 33.8 
    Obstetrics and gynecology hospital 703 27,640 20,878 32.4 
    Orthopaedic hospital 558 18,145 14,287 27.0 
    ENT hospital 89 24,061 19,246 25.0 
   Psychiatric hospital 920 29,606 25,354 16.8 
    Hematonosis hospital 10 99,115 85,802 15.5 
    Cardiovascular hospital 79 108,461 94,049 15.3 
    Occupational disease hospital 16 52,880 45,866 15.3 
    Tumor hospital 135 372,513 324,137 14.9 
    Tuberculosis hospital 34 121,546 109,549 11.0 
    Children’s hospital 114 236,575 218,898 8.1 
    Chest hospital 20 280,775 263,850 6.4 
    Leprosy hospital 31 4,765 4,670 2.0 
    Hospital for infectious diseases 167 99,161 98,459 0.7 
  Specialty hospital 6023 38,811 31,977 21.4 
 
Notes: (1) Data Source: Health Statistical Yearbook of China (2016). (2) Statistics on medical service revenue 
and costs reflect the average revenue and costs per hospital for the particular medical specialty in year 2015 
(Average medical service revenue = total medical service revenue / number of hospitals; Average medical 
service costs = total medical service costs / number of hospitals.); statistics for psychiatric hospital are shown in 
bold. (3) The profit rates are based on the authors’ calculation. Profit rate = (average medical services revenue – 
average medical service costs) / average medical service costs.  
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Table 4. Estimated Availability of New Molecular Entities (NME) for Diseases of Central 
Nervous System (CNS) and Other NCDs: China vs. U.S. (2008-2012) 
Country NME/Global NME China US 
Difference 
(NME in U.S. – NME in China) 
NMEs for CNS Diseases 1/12 8/12 0.583 
NMEs for Other NCDs 11/62 42/62 0.500 
Difference 
(Drugs for other NCDs - CNS drugs) 
0.094 0.010 
0.083 
(Difference in difference) 
 
Notes: (1) Data Source: Global Outlook for Medicines through 2018 - IMS Institute for Healthcare Informatics 
(2014).  (2) New molecular entities (NME) include small molecule and biologic pharmaceutical products where 
at least one of the ingredients is novel. The availability of Global NMEs is measured by the number of NMEs 
with global launch in at least one country between 2008 and 2012. The availability of country NMEs is measured 
by the number of global NMEs available in a specific country by the end of 2013. (3) CNS drugs are drugs 
designed for treating illness in central nervous system, which are mainly related to mental health problems. 
NMEs for other NCDs (Non-communicable Diseases) include drugs for cardiovascular diseases, diabetes and 
tumor. 
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Table 5. Time lag between U.S. and China in the approval/marketing for new atypical 
antipsychotic (AAP) drugs for the treatment of schizophrenia, 1989-2016 
AAP Drugs Year Approved by FDA Whether Marketed in China by 2016 
Clozapine 1989 yes 
Risperidone 1993 yes 
Olanzapine 1996 yes 
Quetiapine 1997 yes 
Ziprasidone 2001 yes 
Aripiprazole 2002 yes 
Paliperidone 2006 yes 
Iloperidone 2009 no 
Asenapine 2009 no 
Paliperidone palmitate 2009 yes 
Lurasidone 2010 no 
Aripiprazole lauroxil 2015 no 
Brexpiprazole 2015 no 
Cariprazine 2015 no 
 
Notes: (1) Data Source: U.S. Food and Drug Administration; China Food and Drug Administration. (2) Drugs 
listed in the table are USFDA-approved atypical antipsychotic (AAP) medicine used to treat schizophrenia by 
2016.  
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Table 6. Major Antidepressants and Whether They are Recommended as First-line 
Therapy for Treating Depression in Different Countries  
Whether recommended as 
first-line therapy for 
depressive disorders 
U.S. 
Guideline 
(2010) 
U.K. 
Guideline 
(2009) 
Canada 
Guideline 
(2016) 
China 
Guideline 
(2006) 
China 
Guideline 
(2015) 
Treatment 
practice in China 
MAOIs       
TCAs    Yes  Yes 
TeCAs Yes Yes    Yes 
SSRIs Yes Yes Yes  Yes  
SNRIs Yes  Yes  Yes  
NaSSAs Yes  Yes  Yes  
NDRIs Yes  Yes    
 
Notes: (1) Data Source: Practice Guideline for the Treatment of Patients with Major Depressive Disorder 
(2010) by American Psychological Association; Depression in Adults with a chronic physical health problem: 
Treatment and Management (2009) by the National Institute for Health and Care Excellence (NICE); Canadian 
Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of 
Adults with Major Depressive Disorder: Introduction and Methods; Clinical Guidelines for treatment-
Psychiatry (2006) by Chinese Medical Association (CMA); Guidelines for the Prevention and Treatment of 
Depression in China (2015) by Chinese Medical Association (CMA). (2) Drugs listed in the table are major 
categories of medicines used to treat depression. (3) The last column, treatment practice in China, reflects the 
main drugs in current usage for the majority of Chinese regions based on the reports in Guidelines for the 
Prevention and Treatment of Depression in China (2015).  
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Table 7.  Name Tags of Mental Illnesses as a Source of Stigma in Chinese Language 
English name for 
 mental illness 
Chinese name with stigmatic bias, 
followed by literal English translation 
Neutral name that avoids stigma, 
followed by literal English translation 
Dementia 痴呆症 失智症 
 Mentally Retarded Loss of Mental Capability 
Schizophrenia 精神分裂症 思觉失调症 
 Mentally Split Early Psychosis Disorder 
Bipolar Disorder 躁郁症 双向情感障碍 
 Choleric and Depressed Bipolar Disorder 
Paranoid Disorder 妄想症 偏执性精神障碍 
 Hallucination Paranoid Disorder 
Alzheimer's Disease 老年痴呆症 阿尔茨海默氏症 
 Old-age Mental Retard  Alzheimer's Disease 
 
Notes: (1) Chinese names with stigmatic bias are the name tags for mental illnesses commonly used in 
mainland China. (2) Neutral names for Dementia and Schizophrenia are name tags adopted in Taiwan, neutral 
names for other mental illnesses are the recommended name tags in Chinese.  
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Figure 1 Regional Variation in the Effective Reimbursement Rates for Mental Healthcare 
in 11 Provinces of China (1989-2011). 
 
 
Notes: (1) Data source: China Health and Nutrition Survey (CHNS, 1989-2011). (2) Effective 
reimbursement rate is calculated as the patient out-of-pocket cost (total medical spending less the medical 
cost covered by insurance) expressed as a percentage of total medical spending for the most recent 
treatment for mental health conditions. (3) Caution: only 4 provinces in East China (Beijing, Shanghai, 
Jiangsu, Shandong), 2 provinces in Northeast China (Liaoning, Heilongjiang), 3 provinces in Middle 
China (Henan, Hubei, Hunan) and 3 provinces in West China (Guangxi, Guizhou, Chongqing) are 
covered in the sample. Sample may not be nationally representative.  
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Figure 2. Density of Hospital Beds in Psychiatric Departments per 1,000 Population in 
China’s All Provinces, 2015. 
 
Data Source: Health Statistical Yearbook of China (2016).  
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Figure 3. Initial Market of New Molecular Entities (NMEs) as a Percentage of All NME 
Launches for Various Countries, 2007-2015 
 
Notes: (1) Data Source: Constructing a sustainable Chinese Pharmaceutical Innovation Ecosystem (2016), by 
China Pharmaceutical Enterprises Association, et al. (in Chinese) (2) Percentage of initial market of NMEs= 
NMEs launched in a certain country as initial market / total number of NMEs marketed globally. Only new 
molecular entities (NMEs) between 2007 and 2015 are included in the calculation. (3) Launching NMEs as 
initial market in a country partially indicates the drug R&D strength of the country, thus the percentage of 
initial market illustrated in the figure partially indicates the relative R&D strength for innovative 
pharmaceutical products in a country compared to other countries in the world.  
 
  
56.3%
12.6%
7.7% 6.5%
3.1% 2.5% 1.8% 1.5% 0.9% 0.9% 0.3%
P
er
ce
n
ta
g
e 
o
f 
in
it
ia
l 
m
ar
k
et
 o
f 
N
M
E
s
39 
 
 
Figure 4. Percentage of Outpatient and Emergency Visits by Types of Healthcare Services 
in China, 2015. 
 
Notes: (1) Data Source: Health Statistical Yearbook of China (2016). (2) Services with percentage less than 
1% are not annotated in this figure. 
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Figure 5. Percentage of Hospital Discharge by Types of Healthcare Services in China, 2015.
 
Notes: (1) Data Source: Health Statistical Yearbook of China (2016). (2) Services with percentage less than 
1% are not annotated in this figure. 
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